Age-based outcomes in kidney cancer patients treated with first-line targeted therapy or immunotherapy
This study compared disease outcomes, treatments, and dose reductions in patients undergoing first-line treatment with targeted therapy or immune checkpoint inhibitor therapy (immunotherapy) for metastatic renal cell carcinoma (RCC) according to age. Patients aged ≥75 years had a longer time from diagnosis to start of treatment with targeted therapy than those aged <65 years and […]